These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 36084269)

  • 1. A UPLC-MS/MS Method for Plasma Biological Monitoring of Nirmatrelvir and Ritonavir in the Context of SARS-CoV-2 Infection and Application to a Case.
    Guyon J; Novion M; Fulda V; Ducint D; Molimard M; Couzi L; Kaminski H; Salvo F; Bouchet S
    J Am Soc Mass Spectrom; 2022 Oct; 33(10):1975-1981. PubMed ID: 36084269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous quantification of nirmatrelvir and ritonavir by LC-MS/MS in patients treated for COVID-19.
    Martens-Lobenhoffer J; Böger CR; Kielstein J; Bode-Böger SM
    J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Dec; 1212():123510. PubMed ID: 36274268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nirmatrelvir/ritonavir treatment in SARS-CoV-2 positive kidney transplant recipients - a case series with four patients.
    Schneider J; Wobser R; Kühn W; Wagner D; Tanriver Y; Walz G
    BMC Nephrol; 2023 Apr; 24(1):99. PubMed ID: 37061677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Saving lives with nirmatrelvir/ritonavir one transplant patient at a time".
    Belden KA; Yeager S; Schulte J; Cantarin MPM; Moss S; Royer T; Coppock D
    Transpl Infect Dis; 2023 Apr; 25(2):e14037. PubMed ID: 36847419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adaptative Strategy of Immunosuppressive Drugs Dosage Adjustments When Combined With Nirmatrelvir/Ritonavir in Solid Organ Transplant Recipients With COVID-19.
    Boland L; Devresse A; Monchaud C; Briol S; Belaiche S; Giguet B; Couzi L; Thaunat O; Esposito L; Meszaros M; Roussoulieres A; Haufroid V; Le Meur Y; Lemaitre F
    Transpl Int; 2024; 37():12360. PubMed ID: 38596505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous measurement of COVID-19 treatment drugs (nirmatrelvir and ritonavir) in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study.
    Zhou CJ; Liu YN; Wang A; Wu H; Xu RA; Zhang Q
    Heliyon; 2024 Jun; 10(11):e32187. PubMed ID: 38868075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management and Outcome of COVID-19 Infection Using Nirmatrelvir/Ritonavir in Kidney Transplant Patients.
    Giguère P; Deschenes MJ; Van Loon M; Hoar S; Fairhead T; Pazhekattu R; Knoll G; Karpinski J; Parikh N; McDougall J; McGuinty M; Hiremath S
    Clin J Am Soc Nephrol; 2023 Jul; 18(7):913-919. PubMed ID: 37099447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tacrolimus Drug-Drug Interaction with Nirmatrelvir/Ritonavir (Paxlovid™) Managed with Phenytoin.
    Sindelar M; McCabe D; Carroll E
    J Med Toxicol; 2023 Jan; 19(1):45-48. PubMed ID: 36536192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nirmatrelvir/ritonavir-induced elevation of blood tacrolimus levels in a patient in the maintenance phase post liver transplantation.
    Shiohira H; Arakaki S; Uehara W; Uehara H; Yamamoto K; Nakamura K
    J Infect Chemother; 2024 Jan; 30(1):77-80. PubMed ID: 37689137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous determination of nirmatrelvir and ritonavir in human plasma using LC-MS/MS and its pharmacokinetic application in healthy Chinese volunteers.
    Liu C; Zhu M; Cao L; Boucetta H; Song M; Hang T; Lu Y
    Biomed Chromatogr; 2022 Nov; 36(11):e5456. PubMed ID: 35881032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-drug interactions of ritonavir-boosted SARS-CoV-2 protease inhibitors in solid organ transplant recipients: experience from the initial use of lopinavir-ritonavir.
    Gonzalez-García R; Roma JR; Rodríguez-García M; Arranz N; Ambrosioni J; Bodro M; Castel MÁ; Cofan F; Crespo G; Diekmann F; Farrero M; Forner A; LLigoña A; Marcos MÁ; Moreno A; Ruiz P; Soy D; Brunet M; Miró JM; Tuset M
    Clin Microbiol Infect; 2023 May; 29(5):655.e1-655.e4. PubMed ID: 36641051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenytoin enzyme induction for management of supratherapeutic tacrolimus levels due to drug-drug interaction with nirmatrelvir/ritonavir: Case series and discussion.
    Marsh J; Logan AT; Bilgili EP; Bowman LJ; Webb AR
    Am J Health Syst Pharm; 2024 Jun; 81(13):e345-e352. PubMed ID: 38347740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nirmatrelvir increases blood tacrolimus concentration in COVID-19 patients as determined by UHPLC-MS/MS method.
    Wu QG; Zeng LY; Li F; Zhu ZQ; Yin L; Meng XM; Zhang L; Zhang P; Jiang XH; Ling Y; Zhang LJ
    Eur Rev Med Pharmacol Sci; 2023 Jan; 27(2):818-825. PubMed ID: 36734723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nirmatrelvir/ritonavir Use With Tacrolimus in Lung Transplant Recipients: A Single-center Case Series.
    Dewey KW; Yen B; Lazo J; Seijo L; Jariwala R; Shah RJ; Quan D; Carpenter B; Paul Singer J; Breen K; Hays S; Florez R
    Transplantation; 2023 May; 107(5):1200-1205. PubMed ID: 36525555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nirmatrelvir/ritonavir treatment of patients with COVID-19 taking tacrolimus: case series describing the results of drug-drug interactions.
    Shen D; Gong Y; Qian Y; Zhu J; Gao J
    J Int Med Res; 2024 May; 52(5):3000605241247705. PubMed ID: 38698526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing the use of nirmatrelvir/ritonavir in solid organ transplant recipients with COVID-19: A review of immunosuppressant adjustment strategies.
    Tang Y; Li Y; Song T
    Front Immunol; 2023; 14():1150341. PubMed ID: 37081880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Drug Monitoring and Dosage Adjustments of Immunosuppressive Drugs When Combined With Nirmatrelvir/Ritonavir in Patients With COVID-19.
    Lemaitre F; Budde K; Van Gelder T; Bergan S; Lawson R; Noceti O; Venkataramanan R; Elens L; Moes DJAR; Hesselink DA; Pawinski T; Johnson-Davis KL; De Winter BCM; Pattanaik S; Brunet M; Masuda S; Langman LJ
    Ther Drug Monit; 2023 Apr; 45(2):191-199. PubMed ID: 35944126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A model-based pharmacokinetic assessment of drug-drug interaction between tacrolimus and nirmatrelvir/ritonavir in a kidney transplant patient with COVID-19.
    Tomida T; Itohara K; Yamamoto K; Kimura T; Fujita K; Uda A; Kitahiro Y; Yokoyama N; Hyodo Y; Omura T; Yano I
    Drug Metab Pharmacokinet; 2023 Dec; 53():100529. PubMed ID: 37924724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case report of drug interaction between co-packaged nirmatrelvir-ritonavir and tacrolimus causing hyponatremia in a lung transplant recipient.
    Lo CM; Chen WH; Tsai MY; Lu HI; Hsiao YH; Chuang KH; Chen Y; Wu HF; Huang KT; Wang YH
    J Cardiothorac Surg; 2024 Mar; 19(1):132. PubMed ID: 38491538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated tacrolimus levels after treatment with nirmatrelvir/ritonavir (Paxlovid) for COVID-19 infection in a child with a kidney transplant.
    Young C; Papiro T; Greenberg JH
    Pediatr Nephrol; 2023 Apr; 38(4):1387-1388. PubMed ID: 35982345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.